Pharmaceutical

Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.

Sep 20, 2024 - 04:00
Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.
Read the original article

Tags:

Previous Article

Biotechs investigate ways to adapt to new clinical trial regulation and economic...

Next Article

AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Top Senate Republican signals interest in site-neutral reform for hospitals

STAT+: Top Senate Republican signals interest in site-n...

Jun 8, 2023

STAT+: Crinetics acromegaly drug succeeds in late-stage trial but would face stiff competition if approved

STAT+: Crinetics acromegaly drug succeeds in late-stage...

Sep 10, 2023

STAT+: Pharmalittle: Three big drugmakers spent less on lobbying after leaving PhRMA; EMA reviews CRO over data concerns

STAT+: Pharmalittle: Three big drugmakers spent less on...

Jul 24, 2023